Breaking News Instant updates and real-time market news.

ABT

Abbott

$83.47

0.3 (0.36%)

, ADPT

Adaptive Biotechnologies

$38.80

-1.79 (-4.41%)

11:55
09/24/19
09/24
11:55
09/24/19
11:55

William Blair diagnostic products/med tech analyst to hold a group luncheon

Diagnostic Products & Med Tech Analyst to hold a group luncheon in New York on September 24 at 12:30 pm hosted by William Blair.

ABT

Abbott

$83.47

0.3 (0.36%)

ADPT

Adaptive Biotechnologies

$38.80

-1.79 (-4.41%)

BDX

Becton Dickinson

$253.34

-0.035 (-0.01%)

COO

Cooper Companies

$300.30

-1.82 (-0.60%)

EXAS

Exact Sciences

$100.06

-3.57 (-3.44%)

GH

Guardant Health

$73.51

-0.2 (-0.27%)

NEO

NeoGenomics

$20.85

-0.75 (-3.47%)

LMNX

Luminex

$22.00

-0.35 (-1.57%)

HAE

Haemonetics

$127.60

-0.93 (-0.72%)

STAA

STAAR Surgical

$28.50

-0.82 (-2.80%)

QGEN

Qiagen

$33.49

-0.015 (-0.04%)

NVTA

Invitae

$19.87

-1.09 (-5.20%)

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

  • 02

    Oct

  • 16

    Oct

  • 01

    Nov

  • 13

    Nov

  • 05

    Dec

ABT Abbott
$83.47

0.3 (0.36%)

07/18/19
BMOC
07/18/19
NO CHANGE
Target $94
BMOC
Outperform
Abbott price target raised to $94 from $87 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Abbott to $94 and kept her Outperform rating after its Q2 earnings beat and a raise in FY19 guidance, saying the company is among a "handful" of medtech names that deliver above-market revenue and double-digit earnings growth along with operating leverage. The analyst notes that following its AbbVie spinoff and acquisition of St. Jude Medical and Alere, Abbott's growth drivers of Alinity, Libre and MitraClip are "humming along" - a trend she expects to continue.
07/18/19
JEFF
07/18/19
NO CHANGE
Target $98
JEFF
Buy
Abbott price target raised to $98 from $80 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Abbott Laboratories to $98 from $80 saying the company's growth story is "still going strong" following its Q2 results. The quarter is more proof that the pharma exit and medtech "double-down" was right move, Denhoy tells investors in a research note. Despite Abbott's "strong" current momentum, each product cycle is still in early innings, adds the analyst. He keeps a Buy rating on the shares.
09/23/19
PIPR
09/23/19
NO CHANGE
Target $182
PIPR
Overweight
DexCom remains a 'must own' stock for investors, says Piper Jaffray
After hosting meetings with management, Piper Jaffray analyst JP McKim believes DexCom (DXCM) remains "a must own for investors." First off, the analyst does not believe the company was "walking down" numbers at a recent investor conference. Continuous glucose monitoring demand remains "robust" and importantly, G7 is only 12-15 months away, McKim tells investors in a research note. The analyst also left the meetings "with a lot more bullishness" on the hospital market as well as the non-intensive Type 2 market, where he believes DexCom's sensor technology will have an impact. McKim does expect share volatility around the near-term approval of Abbott's (ABT) Libre 2.0 with integrated continuous glucose monitoring, but he believes the impact DexCom "will be short lived in nature." McKim keeps an Overweight rating on the shares with a $182 price target. The stock closed Friday down 59c to $154.40.
07/18/19
COWN
07/18/19
NO CHANGE
Target $95
COWN
Outperform
Abbott price target raised to $95 from $86 at Cowen
Cowen analyst Joshua Jennings raised his price target on Abbott to $95 from $86 following Q2 earnings. The analyst said the quarter's highlight was the organic sales growth of 7.5% which was above its target of 7.0%, reflecting continued strength for Libre, MitraClip, and Alinity. He noted management raised it guidance for organic sales growth and earnings and he believes the company can continue to post above consensus results in the second half of the year. Jennings reiterated his Outperform rating on Abbott shares.
ADPT Adaptive Biotechnologies
$38.80

-1.79 (-4.41%)

07/22/19
WBLR
07/22/19
INITIATION
WBLR
Outperform
Adaptive Biotechnologies initiated with an Outperform at William Blair
William Blair analyst Brian Weinstein started Adaptive Biotechnologies with an Outperform rating saying the company's technology holds the promise to enable researchers, commercial partners, and ultimately clinicians to better diagnose and treat disease. The analyst sees potential for upside to revenue targets.
07/23/19
BTIG
07/23/19
INITIATION
Target $46
BTIG
Buy
Adaptive Biotechnologies initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Adaptive Biotechnologies (ADPT) with a Buy rating and a price target of $46, saying the company's "clinical immunomics database" represents its "differentiating asset" and offers "incredible value" to biopharma companies. The analyst further cites Adaptive Biotechnologies' partnership with Roche (RHHBY) that should allow it to develop new diagnostics for early detection of diseases where antigens are unknown and also its "strategic" deal with Microsoft (MSFT), whose machine learning capabilities support its immune medicine platform.
07/23/19
07/23/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Buy at Rosenblatt, while Twitter (TWTR) was initiated with a Neutral. 2. Silicon Labs (SLAB) initiated with a Buy at Benchmark, while Intel (INTC) and Xilinx (XLNX) were initiated with Hold ratings. 3. Cambridge Bancorp (CATC) initiated with a Market Perform at Keefe Bruyette. 4. Broadcom (AVGO) assumed with an Outperform at RBC Capital. 5. Adaptive Biotechnologies (ADPT) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/22/19
GUGG
07/22/19
INITIATION
Target $47
GUGG
Buy
Adaptive Biotechnologies initiated with a Buy at Guggenheim
Guggenheim analyst David Westenberg initiated Adaptive Biotechnologies with a Buy and $47 price target.
BDX Becton Dickinson
$253.34

-0.035 (-0.01%)

05/13/19
WELS
05/13/19
NO CHANGE
Target $265
WELS
Outperform
Becton Dickinson price target lowered to $265 from $280 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen lowered his price target for Becton Dickinson to $265 from $280 after the company reported mixed Q2 results and maintained 2019 underlying sales growth guidance while lowering the EPS outlook. The analyst reiterates an Outperform rating on the shares.
05/13/19
05/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/19
ARGS
06/21/19
NO CHANGE
Target $290
ARGS
Buy
FDA advisory committee review of Becton Dickinson's DCB's a positive, says Argus
Argus analyst David Toung kept his Buy rating and $290 price target on Becton Dickinson, saying the recommendation by the FDA advisory committee that the company performs additional evaluation of the long-term safety of its drug-coated balloons, or DCBs, is a "positive" for the stock. The analyst states that the committee "notably" highlighted the benefit of the balloons and did not recommend that the product is removed from the market. Toung adds that as Becton Dickinson progresses with its acquisition of C.R. Bard, it is "delivering" on revenue growth, margin expansion, and revenue synergies, even though the regulatory advisory from the FDA has lowered his assumed FY19 and FY20 EPS view by 45c and 25c to $11.75 and $13.15 respectively.
08/06/19
PIPR
08/06/19
NO CHANGE
PIPR
Becton Dickinson price target lowered to $266 from $267 at Piper Jaffray
Piper Jaffray analyst William Quirk maintained an Overweight rating on Becton Dickinson, but lowered his price target on shares to $266 from $267, following the company's Q3 earnings results. Quirk said the quarter, which beat on EPS and missed slightly on revenue, with management reiterating FY19 guidance, was "good, not great." The analyst also noted that Becton Dickinson is accelerating the growth curve in the second half of the year, which he called a "positive indicator."
COO Cooper Companies
$300.30

-1.82 (-0.60%)

08/30/19
KEYB
08/30/19
NO CHANGE
KEYB
Cooper Companies Q3 sales miss 'a modest blip,' says KeyBanc
KeyBanc analyst Matthew Mishan reiterated an Overweight rating and $351 price target on Cooper Companies, calling the Q3 sales miss a "modest blip" and saying he remained confident the company can sustain momentum going forward. However, Mishan noted that the stock is likely to trade lower due to the sale miss in the near term.
08/30/19
PIPR
08/30/19
NO CHANGE
Target $360
PIPR
Overweight
Cooper Companies earnings selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using today's post-earnings selloff in shares of Cooper Companies as a buying opportunity. The fiscal Q3 sales miss was largely driven by tough comps in CooperVision and "self-inflicted wounds" in CooperSurgical where the company halted Paragard TV ad spend, O'Brien tells investors in a research note. While frustrating, none of the issues in the quarter appear particularly likely to meaningfully weigh on Cooper results going forward, says the analyst. He points out management was adamant that nothing has changed in the lens market. The market remains healthy and the trade-up to daily lenses should continue to lift Cooper results for years to come, contends O'Brien, who reiterates an Overweight rating on the shares with a $360 price target.
08/22/19
KEYB
08/22/19
NO CHANGE
Target $351
KEYB
Overweight
Cooper Companies price target raised to $351 from $314 at KeyBanc
KeyBanc analyst Matthew Mishan raised his price target for Cooper Companies (COO) to $351 from $314 as he believes the company is positioned to sustain momentum, while avoiding complacency as changes in competitive landscape eventually emerge. More specifically, the analyst thinks market growth appears healthy, Cooper is still playing offense on daily SiHy, key accounts, and specialty lenses, the EssilorLuxotica (ESLOY) and GrandVision combo may be positive for the company, and Key First Look credit card data indicates Hubble growth has decelerated. Mishan reiterates an Overweight rating on the shares.
08/13/19
PIPR
08/13/19
NO CHANGE
Target $360
PIPR
Overweight
Cooper Companies price target raised to $360 from $330 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Cooper Companies to $360 from $330 saying his check in with a contact lens distributor is "very bullish" for the market. The shift to daily lenses continues, with roughly 60% of new fits in this modality, O'Brien tells investors in a research note. His contact believes the market will grow high single digits this year and potentially 10%, "which is as bullish as we have heard from this check," says O'Brien. The analyst has confidence in his second half of 2019 revenue estimates for Cooper Companies and remains constructive on the stock with an Overweight rating.
EXAS Exact Sciences
$100.06

-3.57 (-3.44%)

09/23/19
BNCH
09/23/19
UPGRADE
Target $130
BNCH
Buy
Exact Sciences upgraded to Buy from Hold at Benchmark
Benchmark analyst Bruce Jackson upgraded Exact Sciences to Buy from Hold after the FDA approved its Cologuard colorectal cancer screening test for eligible average-risk individuals ages 45 and older, expanding on its previous indication for ages 50 and older. The analyst, who said Q3 should be strong given historic ordering patterns, raised his estimates for 2019 and set a $130 price target on Exact Sciences shares.
07/30/19
CHLM
07/30/19
NO CHANGE
Target $127
CHLM
Buy
Exact Sciences price target raised to $127 from $115 at Craig-Hallum
Craig-Hallum analyst Per Ostlund raised his price target for Exact Sciences to $127 from $115 following "exceptional" Q2 results that were overshadowed by the planned Genomic Health acquisition. The analyst reiterates a Buy rating on the shares and thinks management has earned investors' faith.
09/10/19
ADAM
09/10/19
NO CHANGE
Target $135
ADAM
Buy
Exact Sciences weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro said he remains a buyer of Exact Sciences following its recent decline of 10%. He said the dip was part of an overall selloff in diagnostic stocks where much of the alpha in the overall stock market has come from. He also thinks certain funds have been pressuring the shares following a cost effectiveness study which he said contains many flaws. Massaro reiterated his Buy rating and $135 price target on Exact Sciences shares.
09/10/19
WBLR
09/10/19
NO CHANGE
WBLR
Outperform
Exact Sciences shares hurt by misunderstanding of paper, says William Blair
William Blair analyst Brian Weinstein attributes yesterday's selloff in shares of Exact Sciences to the "ugly healthcare tape" as well as an article published last week in PLoS One that "once again" looked at cost effectiveness of various colon cancer screening methodologies. However, the article is more of an academic exercise than anything that could affect actual reimbursement or guideline inclusion, Weinstein tells investors in a research note. As such, he believes yesterday's selloff in Exact Sciences shares "is overdone as it relates to this issue." Weinstein writes, "We see nothing new that happened Monday other than a weak market taking down valuations in the sector and a misunderstanding of an academic paper by a class of uneducated investors as it relates to Exact Sciences." He keeps an Outperform rating on the shares.
GH Guardant Health
$73.51

-0.2 (-0.27%)

09/12/19
LEER
09/12/19
NO CHANGE
Target $130
LEER
Outperform
Guardant Health recent weakness a buying opportunity, says SVB Leerink
SVB Leerink analyst Puneet Souda views Guardant Health as a best-in-class liquid biopsy opportunity in a massive high growth market, with the company generating a conservative 60% revenue CAGR that is likely to accelerate as the overall LBx market grows. The analyst highlights buying opportunity amid recent weakness, and reiterates an Outperform rating and $130 price target on the shares given the catalyst path ahead over the next year.
09/11/19
ADAM
09/11/19
NO CHANGE
Target $125
ADAM
Buy
Guardant Health should be bought on weakness, says Canaccord
In an earlier research note to investors, Canaccord analyst Mark Massaro reiterated a Buy rating and $125 price on Guardant Health shares, and noted that he met with Guardant Health co-founder and CEO Helmy Eltoukhy and CFO Derek Bertocci. The analyst says the CEO touted innovation, risk-taking, and TAM expansion, and indicated that the analyst's $120B global TAM estimate for Guardant is "not far off." Further, as the company launches new franchises, it sees geometric increases in available market size, and overlapping growth cycles for many years to come, the analyst adds. Despite some recent weakness in shares, Massaro would be a buyer on the dip.
08/07/19
ADAM
08/07/19
NO CHANGE
Target $125
ADAM
Buy
Guardant Health price target raised to $125 from $96 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Guardant Health to $125 from $96 following a monster Q2 beat and raise quarter. In addition to its solid revenue growth, gross margins surged. The analyst said he likes the company's long-term strategic thinking, execution, and global vision across cancers in late stage therapy selection, cancer monitoring, and early-stage cancer screening. Massaro reiterated his Buy rating on Guardant Health shares.
08/07/19
JPMS
08/07/19
NO CHANGE
Target $135
JPMS
Overweight
Guardant Health price target raised to $135 from $90 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Guardant Health to $135 from $90 saying the company last night reported "extremely strong" Q2 results. The quarter saw "robust" clinical testing momentum coupled with upside from biopharma and development services, Peterson tells investors in a research note. He continues to view Guardant as a "best-in-class asset in the attractive liquid biopsy space" and reiterates an Overweight rating on the shares.
NEO NeoGenomics
$20.85

-0.75 (-3.47%)

04/23/19
BNCH
04/23/19
NO CHANGE
BNCH
UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark
Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.
03/29/19
NEED
03/29/19
NO CHANGE
Target $22
NEED
Buy
NeoGenomics price target raised to $22 from $19 at Needham
Needham analyst Stephen Unger raised his price target on NeoGenomics to $22 and kept his Buy rating after meeting with its CEO Doug VanOort. The analyst says the discussions left him "incrementally bullish" about the company's prospects driven by the doubling of its sales force to 70 representatives that could potentially increase its test volumes. Unger adds that the company's integration of Genoptix is proceeding as planned with no negative surprises, and the "development of a testing panel using next-generation sequencing remains on track for FDA submission before the end of 2019."
03/12/19
FANA
03/12/19
NO CHANGE
Target $23
FANA
Strong Buy
NeoGenomics target raised to $23 after company visit at First Analysis
First Analysis analyst Joseph Munda raised his price target for NeoGenomics to $23 from $22 and reiterates a Strong Buy rating on the shares after visiting the company's headquarters. The analyst says a "deep dive" with management on the integration of Genoptix and the pharma services business "raised his conviction level" for the shares. NeoGenomics offers a "one-stop oncology testing shop" that is well positioned to scale its pharma services business and continue to take clinical testing market share, Munda tells investors in a research note.
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
LMNX Luminex
$22.00

-0.35 (-1.57%)

09/27/18
PIPR
09/27/18
NO CHANGE
PIPR
Neutral
Piper says about $3.5M of Luminex revenue at risk from Medicare determination
After Palmetto's MolDx released a final local coverage determination that panels of 3-5 pathogens will be covered, but larger panels will not be, Piper Jaffray analyst William Quirk said he believes 51% of the population is covered by MACs that follow MolDX. In terms of the decision's implications for Luminex, Quirk said he sees $3M-$4M in exposure to MolDx Medicare for Luminex's xTAG and Nanosphere tests. He also noted that Luminex management has talked about unbundling to make their panels smaller, which he believes will be the likely outcome. Quirk has a Neutral rating on Luminex shares.
HAE Haemonetics
$127.60

-0.93 (-0.72%)

08/07/19
JMPS
08/07/19
NO CHANGE
Target $145
JMPS
Outperform
Haemonetics price target raised to $145 from $128 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Haemonetics to $145 and kept his Outperform rating after its "strong" above-consensus Q2 results. The analyst believes that the company can generate "impressive" earnings growth over the coming years thanks to the volumes and pricing benefits coming from its Plasma division, as well as through margin expansion, share buybacks, and additional cost-saving initiatives.
08/07/19
JEFF
08/07/19
NO CHANGE
Target $165
JEFF
Buy
Haemonetics price target raised to $165 from $140 at Jefferies
Jefferies analyst Anthony Petrone raised his price target for Haemonetics to $165 from $140 saying the company's fiscal Q1 results reinforced his core thesis. The company offers "significant" earnings upside potential in the years ahead on a combo of Plasma volumes, NexSys benefits, and cost savings, Petrone tells investors in a research note. He believes "things trending in the right direction" for Haemonetics and keeps a Buy rating on the shares. The analyst's upside case is now $200 per share, up from $175.
08/07/19
BRRR
08/07/19
NO CHANGE
Target $139
BRRR
Outperform
Haemonetics price target raised to $139 from $116 at Barrington
Barrington analyst Michael Petusky raised his price target for Haemonetics to $139 from $116 citing the company's "strong" fiscal Q1 results. Strong gross margin was the primary driver of the "exceptionally positive" profitability surprise, Petusky tells investors in a research note. He maintains an Outperform rating on Haemonetics.
08/02/19
JEFF
08/02/19
NO CHANGE
Target $140
JEFF
Buy
Haemonetics price target raised to $140 from $125 at Jefferies
Jefferies analyst Anthony Petrone raised his price target for Haemonetics to $140 from $125 to reflect the company's new reporting structure. The target reflects optically higher growth in Plasma as the customer-centric reporting structure better captures underlying trends in disposables, Petrone tells investors in a research note. Beyond optics, the analyst sees worsening IVIG drug shortages as supportive of upside to Haemonetics' Plasma growth. He keeps a Buy rating on the shares.
STAA STAAR Surgical
$28.50

-0.82 (-2.80%)

05/06/19
BNCH
05/06/19
NO CHANGE
Target $54
BNCH
Buy
STAAR Surgical share reaction to FDA request overdone, says Benchmark
Benchmark analyst Bruce Jackson said the negative reaction in STAAR Surgical shares on Friday was overdone after the company disclosed that the FDA found the information in the supplemental PMA to be insufficient for completion of the review. The revenue impact from a delay, if there is one, would be "pretty minimal," said Jackson, who argues that "investors are essentially getting the U.S. EVO program and the Presbyopia lens for free" at STAAR Surgical's current levels. The analyst, who views the pullback as a buying opportunity, keeps a Buy rating on STAAR shares with a price target of $54.
01/22/19
ADAM
01/22/19
NO CHANGE
Target $40
ADAM
Buy
Canaccord strongly recommends adding to STAAR Surgical, reiterates as a Top Pick
Canaccord analyst Jason Mills strongly recommended investors add to STAAR Surgical positions as he reiterated it as a top small-cap pick for 2019. The analyst believes the company will produce elite revenue growth and gross margin in 2019 and possibly deliver upside to 2019 after "crushing expectations" in 2018. Mills noted the company is expanding production and augmenting its commercial footprint globally in preparation for an enormous, expected wave of ICL adoption both near and long-term. Mills reiterated his Buy rating and $40 price target on STAAR Surgical shares.
02/15/19
BNCH
02/15/19
NO CHANGE
Target $54
BNCH
Buy
STAAR Surgical short report 'comes up short,' says Benchmark
After a short report alleged that STAAR Surgical engaged in channel stuffing with their distributor in China, Benchmark analyst Bruce Jackson stated that he believes the allegations are unlikely. In a note to investors entitled "Report Asserting Channel Stuffing Comes Up Short," Jackson said STAAR ships large amounts of product to China since "it is the largest market in the world for surgical vision correction" and one that is "nowhere near saturation." The analyst, who said he is watching Chinese consumer confidence and tariffs, added that "unsupported conspiracy theories are not on our list." He keeps a Buy rating and $54 price target on STAAR shares and would be a buyer on the weakness caused by the short report.
05/06/19
ADAM
05/06/19
NO CHANGE
Target $38
ADAM
Buy
STAAR Surgical price target lowered to $38 from $43 at Canaccord
Canaccord analyst Jason Mills lowered his price target for STAAR Surgical to $38 from $43, saying he recommends adding to positions, notwithstanding the uncertainty around the timing of EVO ICL approval in the U.S. Mills tells investors in a research note that he came away from a meeting with ophthalmologists, industry consultants and STAAR management at the American Society of Cataract & Refractive Surgeons meeting this weekend "confident" in the firm's near- and long-term ICL growth potential. Mills maintains a Buy rating.
QGEN Qiagen
$33.49

-0.015 (-0.04%)

05/30/19
WOLF
05/30/19
INITIATION
Target $44
WOLF
Peer Perform
Qiagen initiated with a Peer Perform at Wolfe Research
Wolfe Research started Qiagen with a Peer Perform rating and $44 price target.
07/12/19
EXAN
07/12/19
UPGRADE
EXAN
Outperform
Qiagen upgraded to Outperform from Neutral at Exane BNP Paribas
07/16/19
EVER
07/16/19
DOWNGRADE
EVER
In Line
Qiagen downgraded to In Line from Outperform at Evercore ISI
06/21/19
LEHM
06/21/19
NO CHANGE
Target $45
LEHM
Overweight
Qiagen price target raised to $45 from $43 at Barclays
Barclays analyst Jack Meehan raised his price target for Qiagen to $45 from $43 saying the strategy updates at yesterday's analyst day "support continued growth acceleration for the organization." The analyst is pleased with the company's steps to build out its portfolio and he reiterates an Overweight rating on the shares.
NVTA Invitae
$19.87

-1.09 (-5.20%)

07/12/19
BNCH
07/12/19
NO CHANGE
Target $26
BNCH
Buy
Invitae price target raised to $26 after Jungla deal announcement at Benchmark
Benchmark analyst Bruce Jackson raised his price target on Invitae shares to $26 from $22 following the company's announcement of a deal to acquire privately-held Jungla for $50M plus potential milestone payments. The analyst, who said the deal adds to Invitae's hereditary cancer testing capabilities, keeps a Buy rating on the stock.
03/04/19
03/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with an Outperform at SVB Leerink. 2. Invitae (NVTA) initiated with a Buy at Chardan. 3. Immunomedics (IMMU) initiated with a Buy at H.C. Wainwright. 4. Canopy Growth (CGC) initiated with a Neutral at Melius Research. 5. Alector (ALEC) initiated with an Overweight at Morgan Stanley and Barclays, an Outperform at SVB Leerink and Cowen, as well as a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/08/19
OPCO
04/08/19
NO CHANGE
Target $30
OPCO
Outperform
Invitae price target raised to $30 from $21 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Invitae to $30 from $21 based on improved long-term competitive positioning for the company's patient-initiated testing given data presented at the ACMG meeting demonstrating poor performance for a leading DTC genetic test and potential consolidation in DTC market as industry matures and economies of scale, quality/clinical data and regulatory oversight drive market share. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

BA

Boeing

$344.09

-25.04 (-6.78%)

08:31
10/19/19
10/19
08:31
10/19/19
08:31
Periodicals
Boeing recovery getting 'a lot more complicated,' Barron's says »

Boeing shares fell on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GMVHF

GVC Holdings

$0.00

(0.00%)

08:27
10/19/19
10/19
08:27
10/19/19
08:27
Periodicals
GVC Holdings looking like 'a good bet,' Barron's says »

GVC Holdings' stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$22.98

-0.94 (-3.93%)

08:19
10/19/19
10/19
08:19
10/19/19
08:19
Periodicals
Street sees National Vision as a buy, some shorts disagree, Barron's says »

National Vision has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$167.11

2.3 (1.40%)

, HUM

Humana

$289.59

4 (1.40%)

08:13
10/19/19
10/19
08:13
10/19/19
08:13
Periodicals
Healthcare stocks getting 'back on their feet,' Barron's says »

The sector is the second…

CI

Cigna

$167.11

2.3 (1.40%)

HUM

Humana

$289.59

4 (1.40%)

UNH

UnitedHealth

$245.59

1.84 (0.75%)

WCG

WellCare

$274.54

0.09 (0.03%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$123.03

1.47 (1.21%)

TEVA

Teva

$7.50

-0.26 (-3.35%)

AZN

AstraZeneca

$43.86

-0.25 (-0.57%)

BMY

Bristol-Myers

$53.02

0.6 (1.14%)

LLY

Eli Lilly

$108.68

0.24 (0.22%)

GSK

GlaxoSmithKline

$42.52

0.04 (0.09%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

MRK

Merck

$84.68

0.88 (1.05%)

NVS

Novartis

$86.86

-0.395 (-0.45%)

PFE

Pfizer

$36.46

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$46.13

-0.43 (-0.92%)

ANTM

Anthem

$249.55

0.3 (0.12%)

CVS

CVS Health

$66.17

-0.31 (-0.47%)

CNC

Centene

$46.92

-0.28 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

08:03
10/19/19
10/19
08:03
10/19/19
08:03
Periodicals
ConocoPhillips stock looking cheap following selloff, Barron's says »

At a time when Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 19

    Nov

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

, NFLX

Netflix

$275.40

-17.88 (-6.10%)

08:00
10/19/19
10/19
08:00
10/19/19
08:00
Periodicals
Comcast stacking up better than investors might expect, Barron's says »

If cord-cutting…

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

T

AT&T

$38.46

0.64 (1.69%)

DIS

Disney

$130.91

-1.46 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

AKS

AK Steel

$2.45

0.055 (2.30%)

, MT

ArcelorMittal

$14.58

0.03 (0.21%)

07:41
10/19/19
10/19
07:41
10/19/19
07:41
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AKS

AK Steel

$2.45

0.055 (2.30%)

MT

ArcelorMittal

$14.58

0.03 (0.21%)

NUE

Nucor

$51.69

-0.11 (-0.21%)

STLD

Steel Dynamics

$28.71

-0.04 (-0.14%)

TMST

TimkenSteel

$5.42

-0.015 (-0.28%)

X

U.S. Steel

$10.72

0.1 (0.94%)

GM

General Motors

$36.19

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 31

    Oct

  • 01

    Nov

AAVMY

ABN Amro

$0.00

(0.00%)

, BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

04:55
10/19/19
10/19
04:55
10/19/19
04:55
Conference/Events
Institute of International Finance to hold annual meeting »

2019 IIF Annual Meeting…

AAVMY

ABN Amro

$0.00

(0.00%)

BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

BCS

Barclays

$8.48

0.11 (1.31%)

BLK

BlackRock

$445.26

-5.56 (-1.23%)

BNPQY

BNP Paribas

$0.00

(0.00%)

C

Citi

$69.76

0.16 (0.23%)

CAIXY

CaixaBank

$0.00

(0.00%)

CIB

Bancolombia

$49.65

0.12 (0.24%)

CS

Credit Suisse

$12.34

0.045 (0.37%)

EV

Eaton Vance

$44.07

-0.49 (-1.10%)

GS

Goldman Sachs

$206.61

0.13 (0.06%)

HSBC

HSBC

$38.72

-0.165 (-0.42%)

JPM

JPMorgan

$120.60

0.21 (0.17%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

MCO

Moody's

$217.41

-1.33 (-0.61%)

MS

Morgan Stanley

$43.70

0.25 (0.58%)

NYT

New York Times

$29.76

0.21 (0.71%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

RBS

RBS

$6.14

0.205 (3.46%)

RY

Royal Bank of Canada

$81.49

0.38 (0.47%)

SMFG

Sumitomo Mitsui

$6.87

-0.04 (-0.58%)

SPGI

S&P Global

$250.62

-2.15 (-0.85%)

STT

State Street

$63.40

3.69 (6.18%)

UBS

UBS

$11.35

0.09 (0.80%)

V

Visa

$175.83

-2.11 (-1.19%)

ZURVY

Zurich Insurance

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 10

    Nov

  • 12

    Nov

  • 21

    Nov

  • 04

    Dec

  • 10

    Dec

  • 07

    Jan

  • 14

    Jan

  • 14

    Jan

STT

State Street

$63.40

3.69 (6.18%)

20:09
10/18/19
10/18
20:09
10/18/19
20:09
Upgrade
State Street rating change at Keefe Bruyette »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SUN

Sunoco

$32.43

0.32 (1.00%)

19:53
10/18/19
10/18
19:53
10/18/19
19:53
Upgrade
Sunoco rating change at BMO Capital »

Sunoco upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.61

(0.00%)

18:24
10/18/19
10/18
18:24
10/18/19
18:24
Hot Stocks
Tandy Leather CFO Castillo to step down »

Tandy Leather Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.61

(0.00%)

18:23
10/18/19
10/18
18:23
10/18/19
18:23
Hot Stocks
Tandy Leather says most recent annual report statements not reliable »

Tandy Leather Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$236.29

0.99 (0.42%)

18:03
10/18/19
10/18
18:03
10/18/19
18:03
Hot Stocks
U.S. lawmakers request Apple restore HKMapp app in Hong Kong »

U.S. Senators Ron Wyden,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

JPM

JPMorgan

$120.60

0.21 (0.17%)

, FB

Facebook

$185.96

-4.435 (-2.33%)

17:59
10/18/19
10/18
17:59
10/18/19
17:59
Periodicals
JPMorgan CEO says Libra 'a neat idea that will never happen,' Reuters says »

JPMorgan (JPM) CEO Jamie…

JPM

JPMorgan

$120.60

0.21 (0.17%)

FB

Facebook

$185.96

-4.435 (-2.33%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

V

Visa

$175.83

-2.11 (-1.19%)

EBAY

eBay

$38.82

-0.31 (-0.79%)

BKNG

Booking Holdings

$2,012.20

-16.43 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 04

    Nov

  • 21

    Nov

  • 14

    Jan

GLD

SPDR Gold Shares

$140.47

-0.13 (-0.09%)

17:52
10/18/19
10/18
17:52
10/18/19
17:52
Hot Stocks
SPDR Gold Shares holdings rise to 924.64MT from 918.19MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$16.48

0.11 (0.67%)

17:43
10/18/19
10/18
17:43
10/18/19
17:43
Hot Stocks
Teck Resources gets approval for stock buyback for up to 40M class B shares »

Teck Resources has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

OSK

Oshkosh

$77.22

0.46 (0.60%)

17:41
10/18/19
10/18
17:41
10/18/19
17:41
Hot Stocks
Oshkosh awarded $159.14M Army contract for medium tactical vehicle production »

Oshkosh was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 19

    Nov

  • 20

    Nov

OVLY

Oak Valley Bancorp

$16.40

-0.16 (-0.97%)

17:35
10/18/19
10/18
17:35
10/18/19
17:35
Earnings
Oak Valley Bancorp reports Q3 EPS 40c vs. 37c last year »

Reports Q3 NII $10.4M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$0.79

-0.0185 (-2.29%)

17:21
10/18/19
10/18
17:21
10/18/19
17:21
Hot Stocks
FTE Networks receives noncompliance notice from NYSE American »

FTE Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.45

0.0048 (1.07%)

17:12
10/18/19
10/18
17:12
10/18/19
17:12
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLMD

Relmada Therapeutics

$20.18

1.07 (5.60%)

17:10
10/18/19
10/18
17:10
10/18/19
17:10
Syndicate
Breaking Syndicate news story on Relmada Therapeutics »

Relmada Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
10/18/19
10/18
16:55
10/18/19
16:55
General news
Breaking General news story  »

Dallas Federal Reserve…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

, NWS

News Corp

$13.79

-0.11 (-0.79%)

16:51
10/18/19
10/18
16:51
10/18/19
16:51
Periodicals
Facebook reaches pact with News Corp., others for news section, WSJ says »

News Corp. (NWSA) has…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

NWS

News Corp

$13.79

-0.11 (-0.79%)

FB

Facebook

$185.96

-4.435 (-2.33%)

NYT

New York Times

$29.76

0.21 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

WAIR

Wesco Aircraft

$11.01

0.01 (0.09%)

16:46
10/18/19
10/18
16:46
10/18/19
16:46
Conference/Events
Wesco Aircraft to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:41
10/18/19
10/18
16:41
10/18/19
16:41
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix up 7.5% at $3.35…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.